Rationale and design for PACE: Patients with intermittent claudication injected with ALDH bright cells

Emerson C. Perin; Michael Murphy; John P. Cooke; Lem Moyé; Timothy D Henry; Judy Bettencourt; Amir Gahremanpour; Nicholas Leeper; R. David Anderson; William R. Hiatt; Joao A. Lima; Bharath Venkatesh; Shelly L. Sayre; Rachel W. Vojvodic; Doris A. Taylor; Ray F. Ebert; Alan T. Hirsch

doi:10.1016/j.ahj.2014.07.021

Rationale and design for PACE: Patients with intermittent claudication injected with ALDH bright cells

Emerson C. Perin, Michael Murphy, John P. Cooke, Lem Moyé, Timothy D Henry, Judy Bettencourt, Amir Gahremanpour, Nicholas Leeper, R. David Anderson, William R. Hiatt, Joao A. Lima, Bharath Venkatesh, Shelly L. Sayre, Rachel W. Vojvodic, Doris A. Taylor, Ray F. Ebert, Alan T. Hirsch

Medicine - Cardiology Division

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Abstract

Peripheral artery disease (PAD) is recognized as a public health issue because of its prevalence, functional limitations, and increased risk of systemic ischemic events. Current treatments for claudication, the primary symptom in patients with PAD, have limitations. Cells identified using cytosolic enzyme aldehyde dehydrogenase (ALDH) may benefit patients with severe PAD but has not been studied in patients with claudication. PACE is a randomized, double-blind, placebo-controlled clinical trial conducted by the Cardiovascular Cell Therapy Research Network to assess the safety and efficacy of autologous bone marrow-derived ALDH^br cells delivered by direct intramuscular injections in 80 patients with symptom-limiting intermittent claudication. Eligible patients will have a significant stenosis or occlusion of infrainguinal arteries and a resting ankle-brachial index less than 0.90 and will be randomized 1:1 to cell or placebo treatment with a 1-year follow-up. The primary end points are the change in peak walking time and leg collateral arterial anatomy, calf muscle blood flow, and tissue perfusion as determined by magnetic resonance imaging at 6 months compared with baseline. The latter 3 measurements are new physiologic lower extremity tissue perfusion and PAD imaging-based end points that may help to quantify the biologic and mechanistic effects of cell therapy. This trial will collect important mechanistic and clinical information on the safety and efficacy of ALDH^br cells in patients with claudication and provide valuable insight into the utility of advanced magnetic resonance imaging end points.

Original language	English (US)
Pages (from-to)	667-673.e2
Journal	American Heart Journal
Volume	168
Issue number	5
DOIs	https://doi.org/10.1016/j.ahj.2014.07.021
State	Published - Nov 1 2014

Bibliographical note

Funding Information:
Funding for the CCTRN was provided by the NHLBI under cooperative agreement UM1 HL087318-07.

Funding Information:
The authors have completed conflict of interest disclosures and have reported the following. Alan T. Hirsch has 3 research grants at the University of Minnesota from Viromed, AstraZeneca, and Pluristem. He also serves as a consultant for Merck, Bayer, Anges, and Novartis. Joao A. Lima serves is funded as the MRI core laboratory through a grant from CAPRICOR. William R. Hiatt manages all industry funding through Colorado Prevention Center Clinical Research, a nonprofit clinical trials research center affiliate of the University of Colorado. He has grants from the following sponsors related to studies relevant to vascular disease research: AstraZeneca, Janssen, Cardiovascular Systems, Inc., DNAVEC, Kowa, Kyushu University, Pluristem, ReNeuron, Rigel, and Takeda. All remaining authors had no financial interests to disclose. The authors are solely responsible for the design and conduct of this study, all study analyses, the drafting and editing of the manuscript, and its final contents, with assistance in editing by Rebecca Bartow at the Texas Heart Institute.

Publisher Copyright:
© 2014 Elsevier Inc. All rights reserved.

Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/j.ahj.2014.07.021

Find It

Find It at U of M Libraries

Cite this

Perin, E. C., Murphy, M., Cooke, J. P., Moyé, L., Henry, T. D., Bettencourt, J., Gahremanpour, A., Leeper, N., Anderson, R. D., Hiatt, W. R., Lima, J. A., Venkatesh, B., Sayre, S. L., Vojvodic, R. W., Taylor, D. A., Ebert, R. F., & Hirsch, A. T. (2014). Rationale and design for PACE: Patients with intermittent claudication injected with ALDH bright cells. American Heart Journal, 168(5), 667-673.e2. https://doi.org/10.1016/j.ahj.2014.07.021

Perin, EC, Murphy, M, Cooke, JP, Moyé, L, Henry, TD, Bettencourt, J, Gahremanpour, A, Leeper, N, Anderson, RD, Hiatt, WR, Lima, JA, Venkatesh, B, Sayre, SL, Vojvodic, RW, Taylor, DA, Ebert, RF & Hirsch, AT 2014, 'Rationale and design for PACE: Patients with intermittent claudication injected with ALDH bright cells', American Heart Journal, vol. 168, no. 5, pp. 667-673.e2. https://doi.org/10.1016/j.ahj.2014.07.021

@article{8abc36028c9f4b36af89022ca158ff2b,

title = "Rationale and design for PACE: Patients with intermittent claudication injected with ALDH bright cells",

abstract = "Peripheral artery disease (PAD) is recognized as a public health issue because of its prevalence, functional limitations, and increased risk of systemic ischemic events. Current treatments for claudication, the primary symptom in patients with PAD, have limitations. Cells identified using cytosolic enzyme aldehyde dehydrogenase (ALDH) may benefit patients with severe PAD but has not been studied in patients with claudication. PACE is a randomized, double-blind, placebo-controlled clinical trial conducted by the Cardiovascular Cell Therapy Research Network to assess the safety and efficacy of autologous bone marrow-derived ALDHbr cells delivered by direct intramuscular injections in 80 patients with symptom-limiting intermittent claudication. Eligible patients will have a significant stenosis or occlusion of infrainguinal arteries and a resting ankle-brachial index less than 0.90 and will be randomized 1:1 to cell or placebo treatment with a 1-year follow-up. The primary end points are the change in peak walking time and leg collateral arterial anatomy, calf muscle blood flow, and tissue perfusion as determined by magnetic resonance imaging at 6 months compared with baseline. The latter 3 measurements are new physiologic lower extremity tissue perfusion and PAD imaging-based end points that may help to quantify the biologic and mechanistic effects of cell therapy. This trial will collect important mechanistic and clinical information on the safety and efficacy of ALDHbr cells in patients with claudication and provide valuable insight into the utility of advanced magnetic resonance imaging end points.",

author = "Perin, {Emerson C.} and Michael Murphy and Cooke, {John P.} and Lem Moy{\'e} and Henry, {Timothy D} and Judy Bettencourt and Amir Gahremanpour and Nicholas Leeper and Anderson, {R. David} and Hiatt, {William R.} and Lima, {Joao A.} and Bharath Venkatesh and Sayre, {Shelly L.} and Vojvodic, {Rachel W.} and Taylor, {Doris A.} and Ebert, {Ray F.} and Hirsch, {Alan T.}",

note = "Funding Information: Funding for the CCTRN was provided by the NHLBI under cooperative agreement UM1 HL087318-07. Funding Information: The authors have completed conflict of interest disclosures and have reported the following. Alan T. Hirsch has 3 research grants at the University of Minnesota from Viromed, AstraZeneca, and Pluristem. He also serves as a consultant for Merck, Bayer, Anges, and Novartis. Joao A. Lima serves is funded as the MRI core laboratory through a grant from CAPRICOR. William R. Hiatt manages all industry funding through Colorado Prevention Center Clinical Research, a nonprofit clinical trials research center affiliate of the University of Colorado. He has grants from the following sponsors related to studies relevant to vascular disease research: AstraZeneca, Janssen, Cardiovascular Systems, Inc., DNAVEC, Kowa, Kyushu University, Pluristem, ReNeuron, Rigel, and Takeda. All remaining authors had no financial interests to disclose. The authors are solely responsible for the design and conduct of this study, all study analyses, the drafting and editing of the manuscript, and its final contents, with assistance in editing by Rebecca Bartow at the Texas Heart Institute. Publisher Copyright: {\textcopyright} 2014 Elsevier Inc. All rights reserved. Copyright: Copyright 2017 Elsevier B.V., All rights reserved.",

year = "2014",

month = nov,

day = "1",

doi = "10.1016/j.ahj.2014.07.021",

language = "English (US)",

volume = "168",

pages = "667--673.e2",

journal = "American Heart Journal",

issn = "0002-8703",

publisher = "Mosby Inc.",

number = "5",

}

TY - JOUR

T1 - Rationale and design for PACE

T2 - Patients with intermittent claudication injected with ALDH bright cells

AU - Perin, Emerson C.

AU - Murphy, Michael

AU - Cooke, John P.

AU - Moyé, Lem

AU - Henry, Timothy D

AU - Bettencourt, Judy

AU - Gahremanpour, Amir

AU - Leeper, Nicholas

AU - Anderson, R. David

AU - Hiatt, William R.

AU - Lima, Joao A.

AU - Venkatesh, Bharath

AU - Sayre, Shelly L.

AU - Vojvodic, Rachel W.

AU - Taylor, Doris A.

AU - Ebert, Ray F.

AU - Hirsch, Alan T.

N1 - Funding Information: Funding for the CCTRN was provided by the NHLBI under cooperative agreement UM1 HL087318-07. Funding Information: The authors have completed conflict of interest disclosures and have reported the following. Alan T. Hirsch has 3 research grants at the University of Minnesota from Viromed, AstraZeneca, and Pluristem. He also serves as a consultant for Merck, Bayer, Anges, and Novartis. Joao A. Lima serves is funded as the MRI core laboratory through a grant from CAPRICOR. William R. Hiatt manages all industry funding through Colorado Prevention Center Clinical Research, a nonprofit clinical trials research center affiliate of the University of Colorado. He has grants from the following sponsors related to studies relevant to vascular disease research: AstraZeneca, Janssen, Cardiovascular Systems, Inc., DNAVEC, Kowa, Kyushu University, Pluristem, ReNeuron, Rigel, and Takeda. All remaining authors had no financial interests to disclose. The authors are solely responsible for the design and conduct of this study, all study analyses, the drafting and editing of the manuscript, and its final contents, with assistance in editing by Rebecca Bartow at the Texas Heart Institute. Publisher Copyright: © 2014 Elsevier Inc. All rights reserved. Copyright: Copyright 2017 Elsevier B.V., All rights reserved.

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Peripheral artery disease (PAD) is recognized as a public health issue because of its prevalence, functional limitations, and increased risk of systemic ischemic events. Current treatments for claudication, the primary symptom in patients with PAD, have limitations. Cells identified using cytosolic enzyme aldehyde dehydrogenase (ALDH) may benefit patients with severe PAD but has not been studied in patients with claudication. PACE is a randomized, double-blind, placebo-controlled clinical trial conducted by the Cardiovascular Cell Therapy Research Network to assess the safety and efficacy of autologous bone marrow-derived ALDHbr cells delivered by direct intramuscular injections in 80 patients with symptom-limiting intermittent claudication. Eligible patients will have a significant stenosis or occlusion of infrainguinal arteries and a resting ankle-brachial index less than 0.90 and will be randomized 1:1 to cell or placebo treatment with a 1-year follow-up. The primary end points are the change in peak walking time and leg collateral arterial anatomy, calf muscle blood flow, and tissue perfusion as determined by magnetic resonance imaging at 6 months compared with baseline. The latter 3 measurements are new physiologic lower extremity tissue perfusion and PAD imaging-based end points that may help to quantify the biologic and mechanistic effects of cell therapy. This trial will collect important mechanistic and clinical information on the safety and efficacy of ALDHbr cells in patients with claudication and provide valuable insight into the utility of advanced magnetic resonance imaging end points.

AB - Peripheral artery disease (PAD) is recognized as a public health issue because of its prevalence, functional limitations, and increased risk of systemic ischemic events. Current treatments for claudication, the primary symptom in patients with PAD, have limitations. Cells identified using cytosolic enzyme aldehyde dehydrogenase (ALDH) may benefit patients with severe PAD but has not been studied in patients with claudication. PACE is a randomized, double-blind, placebo-controlled clinical trial conducted by the Cardiovascular Cell Therapy Research Network to assess the safety and efficacy of autologous bone marrow-derived ALDHbr cells delivered by direct intramuscular injections in 80 patients with symptom-limiting intermittent claudication. Eligible patients will have a significant stenosis or occlusion of infrainguinal arteries and a resting ankle-brachial index less than 0.90 and will be randomized 1:1 to cell or placebo treatment with a 1-year follow-up. The primary end points are the change in peak walking time and leg collateral arterial anatomy, calf muscle blood flow, and tissue perfusion as determined by magnetic resonance imaging at 6 months compared with baseline. The latter 3 measurements are new physiologic lower extremity tissue perfusion and PAD imaging-based end points that may help to quantify the biologic and mechanistic effects of cell therapy. This trial will collect important mechanistic and clinical information on the safety and efficacy of ALDHbr cells in patients with claudication and provide valuable insight into the utility of advanced magnetic resonance imaging end points.

UR - http://www.scopus.com/inward/record.url?scp=84908332709&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908332709&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2014.07.021

DO - 10.1016/j.ahj.2014.07.021

M3 - Article

C2 - 25440794

AN - SCOPUS:84908332709

SN - 0002-8703

VL - 168

SP - 667-673.e2

JO - American Heart Journal

JF - American Heart Journal

IS - 5

ER -

Rationale and design for PACE: Patients with intermittent claudication injected with ALDH bright cells

Abstract

Bibliographical note

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this